picibanil and Genital-Neoplasms--Female

picibanil has been researched along with Genital-Neoplasms--Female* in 3 studies

Trials

1 trial(s) available for picibanil and Genital-Neoplasms--Female

Article	Year
[Clinical studies of long-term administration of OK-432 in patients with gynecologic cancer]. Nihon Sanka Fujinka Gakkai zasshi, 1989, Volume: 41, Issue:9 The clinical value of OK-432 treatments, was evaluated in 215 patients with various types of gynecologic cancer. Five KE OK-432 was administrated by intramuscular injection every other day for up to 5 years, unless severe side-effects were observed. The 5-year survival rate was determined in 51 patients in the OK-432 group and 93 patients in the control group. The survival rate in the OK-432 group was significantly higher in the cervical cancer patients in stages III and IV than in the control group, at from 20 to 29 months and from 37 to 42 months. These results indicated that long period administration of OK-432 might improve the survival rate in patients with gynecologic cancer, especially in those with advanced cervical cancer. Topics: Adult; Aged; Aged, 80 and over; Biological Products; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Genital Neoplasms, Female; Humans; Injections, Intramuscular; Middle Aged; Neoplasm Staging; Picibanil; Survival Rate; Time Factors; Uterine Cervical Neoplasms	1989

Article

Year

[Clinical studies of long-term administration of OK-432 in patients with gynecologic cancer].

Nihon Sanka Fujinka Gakkai zasshi, 1989, Volume: 41, Issue:9

The clinical value of OK-432 treatments, was evaluated in 215 patients with various types of gynecologic cancer. Five KE OK-432 was administrated by intramuscular injection every other day for up to 5 years, unless severe side-effects were observed. The 5-year survival rate was determined in 51 patients in the OK-432 group and 93 patients in the control group. The survival rate in the OK-432 group was significantly higher in the cervical cancer patients in stages III and IV than in the control group, at from 20 to 29 months and from 37 to 42 months. These results indicated that long period administration of OK-432 might improve the survival rate in patients with gynecologic cancer, especially in those with advanced cervical cancer.

Topics: Adult; Aged; Aged, 80 and over; Biological Products; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Genital Neoplasms, Female; Humans; Injections, Intramuscular; Middle Aged; Neoplasm Staging; Picibanil; Survival Rate; Time Factors; Uterine Cervical Neoplasms

1989

Other Studies

2 other study(ies) available for picibanil and Genital-Neoplasms--Female

Article	Year
Studies of natural killer activity and augmentation by OK-432 in patients with gynecological malignancies. Gynecologic and obstetric investigation, 1986, Volume: 21, Issue:1 The natural killer (NK) and antibody-dependent cellular cytotoxic (ADCC) activities were determined in peripheral blood lymphocytes of patients with gynecologic malignancy. The effects of a preparation of Streptococcus pyogenes (OK-432) and of interferon were determined. Patients with advanced cancer exhibited lower natural cytotoxicity than normal women. NK and ADCC activities were decreased following surgery and NK activity was decreased following chemotherapy. Radiation reduced the percentage of Leu-7-positive cells in the circulation of the patients. OK-432 augmented the NK activity of both healthy women and patients with early malignancy. Interferon was less effective than OK-432 in augmenting NK activity. Topics: Adult; Aged; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Cytotoxicity, Immunologic; Female; Flow Cytometry; Genital Neoplasms, Female; Humans; Interferon Type I; Killer Cells, Natural; Middle Aged; Ovarian Neoplasms; Picibanil; T-Lymphocytes; Uterine Cervical Neoplasms; Uterine Neoplasms; Vulvar Neoplasms	1986
[Clinical value of immunotherapy for gynecological cancer by BRM (biological response modifier)]. Nihon Sanka Fujinka Gakkai zasshi, 1985, Volume: 37, Issue:6 Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; Female; Genital Neoplasms, Female; Humans; Immunotherapy; Interferons; Interleukin-1; Leucine; Levamisole; Picibanil; Thymic Factor, Circulating; Thymosin	1985

Article

Year

Studies of natural killer activity and augmentation by OK-432 in patients with gynecological malignancies.

Gynecologic and obstetric investigation, 1986, Volume: 21, Issue:1

The natural killer (NK) and antibody-dependent cellular cytotoxic (ADCC) activities were determined in peripheral blood lymphocytes of patients with gynecologic malignancy. The effects of a preparation of Streptococcus pyogenes (OK-432) and of interferon were determined. Patients with advanced cancer exhibited lower natural cytotoxicity than normal women. NK and ADCC activities were decreased following surgery and NK activity was decreased following chemotherapy. Radiation reduced the percentage of Leu-7-positive cells in the circulation of the patients. OK-432 augmented the NK activity of both healthy women and patients with early malignancy. Interferon was less effective than OK-432 in augmenting NK activity.

Topics: Adult; Aged; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Cytotoxicity, Immunologic; Female; Flow Cytometry; Genital Neoplasms, Female; Humans; Interferon Type I; Killer Cells, Natural; Middle Aged; Ovarian Neoplasms; Picibanil; T-Lymphocytes; Uterine Cervical Neoplasms; Uterine Neoplasms; Vulvar Neoplasms

1986

[Clinical value of immunotherapy for gynecological cancer by BRM (biological response modifier)].

Nihon Sanka Fujinka Gakkai zasshi, 1985, Volume: 37, Issue:6

Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; Female; Genital Neoplasms, Female; Humans; Immunotherapy; Interferons; Interleukin-1; Leucine; Levamisole; Picibanil; Thymic Factor, Circulating; Thymosin

1985